Another strategy which has recently been evaluated is the design of CD39- expressing CAR-T cells with triple shRNA knockdown of mucin domain-3 (TIM-3), lymphocyte-activation gene and PD-1, T-cell immunoglobulin domain-3 (LAG-3) to enhance their infiltration to the tumor site. The gene discussed is ENTPD1; the disease is neoplasm.